Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Mol Cancer Res. 2017 Nov 13;16(2):296–308. doi: 10.1158/1541-7786.MCR-17-0308

Figure 2. shRNA mediated CCR2 knockdown in DCIS.com breast cancer cells inhibits invasive progression.

Figure 2

A. Flow cytometry analysis for CCR2 expression in Parental (Par) or DCIS.com cells expressing control (Con) or CCR2 shRNA (CCR2-KD). B. Tissue mass of DCIS.com MIND injected mammary glands C. DCIS.com MIND lesions were co-stained for CK5 (red) and α-sma (green) and counterstained with DAPI (blue). Representative images are shown with arrows pointing to invading tumor cells. Lesions were scored for invasiveness. n=152 lesions for control shRNA group, 193 lesions for CCR2-KD group. n=8 mice/group. D-E. Image J quantification of Ki67 (D) or cleaved caspase-3 (E) immunostaining in DCIS.com lesions. Arbitrary units are shown. Arrows point to examples of positive staining. Statistical analysis was performed using One way ANOVA with Bonferonni post-hoc comparison (B, D,E) or Chi square test (C). Statistical significance was determined by p<0.05. *p<0.05, **p<0.01. Scale bar=200 microns.